PER percheron therapeutics limited

Ann: WHO selects proposed INN for ATL1102, page-12

  1. 14,651 Posts.
    lightbulb Created with Sketch. 1583
    Benefit and Cost of Elevidys QuestionedBut while some experts are bullish on approval, others have cited potential drawbacks and concerns about the gene therapy. David Rind, the chief medical officer of the Institute for Clinical and Economic Review (ICER), penned an article in JAMA last week in which he noted that Elevidys missed its primary efficacy endpoint in two studies but still netted approva
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.0¢
Change
0.000(0.00%)
Mkt cap ! $10.87M
Open High Low Value Volume
1.0¢ 1.0¢ 1.0¢ $5.924K 592.3K

Buyers (Bids)

No. Vol. Price($)
1 4056872 1.0¢
 

Sellers (Offers)

Price($) Vol. No.
1.1¢ 3764467 6
View Market Depth
Last trade - 15.43pm 16/06/2025 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.